- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
ENOA Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP2879a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
ENOA Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | P06733 |
| Clone Names | 81020035 |
| Calculated MW | 47169 Da |
ENOA Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 2023 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP2879a was selected from the N-term region of human ENOA. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
ENOA Antibody (N-term) Blocking Peptide - Protein Information | |
| Name ENO1 | |
| Synonyms ENO1L1, MBPB1, MPB1 | |
| Function Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production | |
| Cellular Location Cytoplasm. Cell membrane. Cytoplasm, myofibril, sarcomere, M line. Note=Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line | |
| Tissue Location The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons | |
ENOA Antibody (N-term) Blocking Peptide - Related products
AP2879a: ENOA Antibody (N-term)
AP2879b: ENOA Antibody (C-term)
AP6526c: ENO1 Antibody (Center)
LY10917a: ENO1 Over-expression Lysate
BP2879a: ENOA Antibody (N-term) Blocking Peptide
BP2879b: ENOA Antibody (C-term) Blocking Peptide
BP6526a: ENO1 Antibody (N-term) Blocking Peptide
BP6526c: ENO1 Antibody (Center) Blocking Peptide
ENOA Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
ENO1 is one of three enolase isoenzymes found in mammals; the protein alpha-enolase, a homodimeric soluble enzyme, and is also a shorter monomeric structural lens protein, tau-crystallin. The two proteins are made from the same message. The full length protein, the isoenzyme, is found in the cytoplasm. The shorter protein is produced from an alternative translation start, is localized to the nucleus, and has been found to bind to an element in the c-myc promoter.
REFERENCES
Cappello,P., Int. J. Cancer 125 (3), 639-648 (2009)Wygrecka,M., Blood 113 (22), 5588-5598 (2009)